Hui Zou

Hui Zou

Company: Phanes Therapeutics

Job title: Chief Scientific Officer


Preclinical Studies of PT199, a Humanized mAb That Fully Inhibits Both Membrane Bound & Soluble Serum CD73 11:15 am

• Discussing why the full inhibition of the enzyme activity from both membrane and soluble CD73 is crucial to achieve clinical activity • Exploring how the PD response/biomarker may guide the selection of targeted indications and/or patientsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.